 SILVER SPRING, Md., Feb. 17, 2021 GLOBE NEWSWIRE -- Aziyo Biologics, Inc. Nasdaq: AZYO, a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the first patient enrolled in the HEAL Study, investigating the biologic and clinical effects of device envelopes which are placed around cardiovascular implantable electronic devices CIEDs at the time of implantation surgery. 